Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects

Inclusion Criteria: * Subject provides written informed consent before any study-specific evaluation is performed. * Subject is a healthy adult male or a female of non-childbearing potential between the ages of 18 and 45 years, inclusive. * Subject has a body mass index of 18.5 to 30 kg/m2, inclusive. * Subject has hematology, coagulation, serum chemistry, and urinalysis test results within the reference ranges or showing no clinically relevant deviations, as judged by the Investigator. Exclusion Criteria: * Subject has the presence of an active or recurring clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, neurologic, psychiatric, immunologic, hematologic, gastrointestinal, or metabolic disease requiring medical treatment. * Subject has any surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of K-312. Cholecystectomy is permitted if there are no postcholecystectomy gastrointestinal symptoms. * Subject has clinically relevant abnormalities in clinical laboratory parameters.